Aspen Explains U-Turn On Withdrawing From Proposed API Sale
As South African Firm Wraps Up Major COVID-19 Deal With J&J
Following years of reshaping its operations, one part of Aspen Pharmacare’s business that is to stay for now is the firm’s API division. The South African firm’s management explained why as Aspen presented results from its financial first half, hours after wrapping up a key COVID-19 licensing deal with Johnson & Johnson.
You may also be interested in...
A US FDA review panel has given a lukewarm reception to molnupiravir, while Inovio is assessing its vaccine candidates against the new omicron variant, J&J nears a South African vaccine deal with Aspen, and South Korea brings in new COVID-19 measures. Meanwhile, Serum exports Novavax vaccine, Bharat looks at Covaxin in Omicron and Ocugen's Covaxin trial put on hold.
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.